dx.doi.org
P659 Continuing or stopping 5-aminosalicylate in patients with Inflammatory Bowel Disease under anti-TNF therapy: A nationwide population-based study
January 2023 • Jin Young Seo, S Kim, Subin Song, Sang Hyun Shin, Seonghun Park, S W Hong, Sung Wook Hwang, S H Park, Dong‐Hoon Yang, J S Byeon, Seung‐Jae Myung, S K…
Abstract Background The clinical impact of continuing or stopping 5-aminosalicylate (5-ASA) after escalating to treatment with an anti-tumour necrosis factor (TNF) agent in patients with inflammatory bowel disease (IBD) is currently unclear. We aimed to compare the outcomes of IBD patients who stopped or continued 5-ASA after starting anti-TNF therapy. Methods We analysed data obtained from the Korean National Health Insurance claims database between 2007 and 2020. Our analysis included IBD patients already on 5-A…